Famciclovir Tablets (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Administer famciclovir 250 mg orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of first-episode genital herpes Adults: Administer this medication 250 mg orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes Adults: Administer this medication 125 mg orally 2 times daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer this medication 250 mg orally 2 times daily. Periodically discontinue treatment every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: Since the creatinine clearance of this medication is reduced in patients with renal impairment, dosage adjustment should be undertaken with caution. The dosage for these patients is as follows. 1) Treatment of herpes zoster and first-episode genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg 2 times daily 10～29: 250 mg once daily 2) Treatment of acute recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 125 mg 2 times daily 10～29: 125 mg once daily 3) Suppression of recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg 2 times daily 10～29: 125 mg 2 times daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following equations. Men: {weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis It is preferable to administer this medication every 48 hours, taking the dialysis interval into account. Hemodialysis for 4 hours reduces the plasma concentration of this medication by approximately 75%; therefore, administer this medication immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dosage adjustment is required in patients with compensated chronic liver disease. There is insufficient treatment experience in patients with overt decompensated chronic liver disease; therefore, no clear recommended dosage has been established.

This medication should not be administered to certain patients. First, it should not be used in patients who are allergic to this medication or its components or who have experienced hypersensitivity reactions. Additionally, this medication contains lactose, so it should not be given to patients with genetic metabolic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Patients allergic to soybean oil, soy, or peanuts should also refrain from taking this medication. This medication should be used cautiously in patients with impaired kidney function or those with dyslipidemia, diabetic dyslipidemia, pancreatitis, etc., and it is advisable to regularly check blood lipid levels. Various side effects such as headache, dizziness, nausea, vomiting, abdominal pain, diarrhea, skin rash, and itching may occur while taking this medication; consult a doctor if symptoms are severe or persist. Particularly, elderly patients or those with impaired kidney function may experience central nervous system symptoms such as drowsiness or confusion more frequently, so caution is necessary. This medication does not cure genital herpes; therefore, avoid sexual contact and maintain safe sexual practices if symptoms are present during treatment. Caution is necessary as dizziness or drowsiness may occur while driving or operating machinery. Women who are pregnant or may become pregnant should consider the benefits and risks carefully when administering this medication, and breastfeeding mothers should also use it cautiously. Safety and efficacy in children under 18 years have not been established, so it is advisable not to use it. In case of overdose, seek medical attention immediately for appropriate treatment, and blood dialysis can remove the components of this medication. Store in a sealed container as this medication is sensitive to air and moisture. It is also advisable to store it in a cool, dry place below 30 degrees Celsius and out of reach of children; do not transfer to other containers.

• Headache
• nausea
• thrombocytopenia
• leukopenia and neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations
• vomiting

This medication is sensitive to air and moisture; therefore, it must be stored in a sealed container. Additionally, it is advisable to keep it in a cool, dry place below 30 degrees Celsius.

Appearance

White round film-coated tablet

Package unit

21 tablets/box [(7 tablets/PTP*3)]